ASCO GU 2021 Bladder and Kidney Cancer Videos

Integrating Treatment Advancements of Metastatic Kidney Cancer Into Clinical Practice - Wenxin Xu

The Treatment Landscape for Advanced Urothelial Carcinoma in 2021 - Jonathan Rosenberg

Real World Treatment Patterns in Locally Advanced or Metastatic Urothelial Cancer Patients - Alicia Morgans

Deintensification of Management of Low-Risk NMIBC - Angela Smith

Investigator Initiated Phase I Dose-escalation Trial and 7 Subsequent Expansion Cohorts - Andrea Apolo

Pembrolizumab in the Real-World Setting for Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG - Arjun Balar

Efficacy Assessment of Multiple MET Kinase Inhibitors in Metastatic Papillary Renal Cell Carcinoma - The SWOG1500 PAPMET Trial - Sumanta Pal & Toni Choueiri

Adjuvant Therapy for Improved Disease-Free Survival for Patients with Muscle-Invasive Urothelial Carcinoma Following Radical Surgery - Checkmate 274 - Petros Grivas

A Brief History of POUT & Three-year Updated Outcomes from A Phase III Randomized Trial of Peri-Operative Chemotherapy Vs. Surveillance in UTUC - Alison Birtle

Evolving Landscape for Frontline Treatment in Clear Cell Metastatic Renal Cell Carcinoma - Toni K. Choueiri - Sumanta Kumar Pal

A Preplanned Exploratory Biomarker Analysis in the ctDNA-Positive Patient Population of IMvigor010 - Tom Powles

High-Risk Non-Muscle-Invasive Bladder Cancer - Which Patients Benefit from a Radical Cystectomy - Anne Schuckman

Efficacy by Duration or Number of Cycles of First-line Chemotherapy in the JAVELIN Bladder 100 Study - Petros Grivas

SUB-urothelial DUrvalumab InjEction-1 (SUBDUE-1) - A Clinical Trial for the Novel Administration of Immunotherapy for Bladder Cancer- Dickon Hayne

Immunotherapy in Advanced Urothelial Carcinoma - Ali Khaki

A New Standard of Care in Treatment of Advanced Urothelial Carcinoma from JAVELIN Bladder 100 - Cora Sternberg

Adjuvant Study of Immune Checkpoint Blockade in Patients with Urothelial Carcinoma - Matthew Galsky